Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $19.1754 is 66.60% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 19.19||$ 20|
|Low:||$ 19.13||$ 11.51|
Company Description (as filed with the SEC)
We were founded in 1998 and are a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. We intend to be a leader in specialty medicines focusing on metabolic and gastrointestinal diseases and other specialty disease areas with significant unmet medical needs. Our current pipeline of internal product candidates focuses on specialty gastrointestinal and metabolic diseases. Our portfolio also includes two clinical license collaborations with Boehringer Ingelheim. Since 2003 we have had a license collaboration with Sanofi, or the Sanofi License Agreement, in the diabetes field pertaining to the development and commercialization of lixisenatide, both as a standalone therapy and as a combination therapy. Pursuant to the Sanofi License Agreement, we were entitled to receive certain royalties and commercial milestones in respect of global net-sales of Soliqua® 100/33/ Suliqua® and Lyxumia®/Adlyxin® . ... More ...
Nasdaq Official Price
Apr. 24, 2019
Apr. 23, 2019